Drug Profile

CNP 104

Alternative Names: CNP-104

Latest Information Update: 09 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cour Pharmaceutical Development
Class Peptides; Polymers
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary biliary cirrhosis
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Primary biliary cirrhosis

Most Recent Events

05 May 2026 Efficacy and adverse events data from a phase IIa trial in Primary biliary cirrhosis presented at the Digestive Disease Week 2026 (DDW-2026)
05 May 2026 Cour Pharmaceuticals plans a phase IIb/III trial for Primary biliary cirrhosis
03 Mar 2026 Efficacy data from a phase IIa trial in Primary biliary cirrhosis released by COUR Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com